<PAGE>   1

                                 EXHIBIT INDEX

                        NYMOX PHARMACEUTICAL CORPORATION

                        Form 20-F Registration Statement

<TABLE>
<CAPTION>
     Exhibit No.                         Description
     -----------                         -----------
<S>          <C>     <C> 
Form 20-F    Edgar
---------    -----
1.1          3.1     Articles of Incorporation, as amended, of the Registrant 
                     (filed previously).

1.2          3.2     Bylaws of the Registrant (filed previously).

3.1          10.1    Memorandum of Agreement between Paul Averback and 
                     the Registrant (filed previously).

3.2          10.2    Share Option Plan of the Registrant (filed 
                     previously).

3.3          10.3    Research and License Agreement between the General 
                     Hospital Corporation and the Registrant (filed previously).

3.4          10.4    Sole Non-Exclusive License and Supply Agreement for the 
                     Nymox AD7C(TM) Diagnostic Test for Alzheimer's Disease 
                     between SGS Lab Simon S.A. and the Registrant (filed 
                     previously).

3.5          10.5    Research and License Amendment between the General 
                     Hospital Corporation and the Registrant (filed previously).

3.6          10.6    Sole Non-Exclusive License and Supply Agreement for the 
                     Nymox AD7C(TM) Diagnostic Test for Alzheimer's Disease 
                     between Specialty Laboratories and the Registrant.

</TABLE>

                       SOLE NONEXCLUSIVE U.S. LICENSE AND
                            SUPPLY AGREEMENT FOR THE
                         NYMOX AD7C(TM) DIAGNOSTIC TEST
                            FOR ALZHEIMER'S DISEASE

                        ENTERED INTO ON JANUARY 19, 1999

B Y    A N D    B E T W E E N :

                               NYMOX CORPORATION

     Licensor

                                       31
<PAGE>   2
                                    - and -

                          SPECIALTY LABORATORIES, INC.
Licensee

                       T A B L E    O F    C O N T E N T S
<TABLE>
<CAPTION>
<S>              <C>                                                      <C>
                                                                          Page
ARTICLE 1.       DEFINITIONS                                                3
ARTICLE 2.       PURPOSE OF AGREEMENT                                       6
ARTICLE 3.       CONFIDENTIALITY                                            6
ARTICLE 4.       THE LICENSE                                                7
ARTICLE 5        COMPENSATION TO NYMOX                                      9
ARTICLE 6.       REIMBURSEMENT AND PRICE                                    11
ARTICLE 7.       MARKETING                                                  12
ARTICLE 8.       PERFORMANCE TARGETS/CONVERSION TO 
                 NONEXCLUSIVE LICENSE                                       13
ARTICLE 9.       TERMINATION                                                14
ARTICLE 10.      IMPROVEMENTS                                               16
ARTICLE 11.      RESPONSIBILITIES OF THE PARTIES                            17
ARTICLE 12.      QUALITY CONTROL                                            20
ARTICLE 13.      EFFECT OF LICENSING AGREEMENT                              21
ARTICLE 14.      REPRESENTATIONS AND WARRANTIES                             22
ARTICLE 15.      MISCELLANEOUS PROVISIONS                                   23
EXHIBIT A:       PATENTS LICENSED TO SPECIALTY                              27
EXHIBIT B:       TRADEMARKS LICENSED TO SPECIALTY                           28
ARTICLE 1.       DEFINITIONS
</TABLE>

The terms defined in this Article shall have the following meanings (applicable
to both the singular and plural forms) in this Agreement:

"AD7C(TM) Test" means the Nymox Corporation AD7C(TM) Alzheimer's disease test
for measuring the level of the biomarker Neural Thread Protein (NTP) in
cerebrospinal fluid (CSF), urine, blood or other bodily fluids or tissues.
"AD7C(TM) Test", as used herein, is not intended to include a test kit employing
the AD7C(TM) testing technology for Diagnostic Purposes and sold or intended to
be sold to third parties.

"Affiliate" means any person, firm or corporation legally competent to perform
the services and carry out the terms of this Agreement, which Controls, is
Controlled by or is under common Control with either Nymox Corporation or
Specialty Laboratories, Inc.

"Average Price" means:

     (a)  for AD7C(TM) Tests conducted for Diagnostic Purposes, the Net Revenue
          for AD7C(TM)


                                       32




<PAGE>   3
          Tests conducted for Diagnostic Purposes during a Billing Month,
          divided by the Number of Tests in that Billing Month; or

     (b)  for any Clinical Study Support contract executed by Specialty, the
          price per AD7C(TM) Test as stipulated in the contract, or, if the
          contract does not so stipulate, the Estimated Net Revenue divided by
          the Estimated Number of Tests for that contract.

"Billing Month" (applicable only to the conduct of AD7C(TM) Tests by Specialty
for Diagnostic Purposes) means each calendar month during the period of this
Agreement, beginning with the month during which Launch occurs.

"Billing Quarter" (applicable only to the conduct of AD7C(TM) Tests by Specialty
for Clinical Study Support) means each calendar quarter during the period of
this Agreement, beginning with the quarter during which Launch occurs.

"Clinical Study Support" means the use or performance of the AD7C(TM) Test in
clinical trials of therapeutics in Phases 1, 2, 3 or 4 of an Investigational New
Drug trial.

"Competitor" means any person, firm or corporation, other than Nymox or
Specialty, that offers for sale a diagnostic test for Alzheimer's disease or
that Controls any corporation or partnership that offers a diagnostic test for
Alzheimer's disease.

"Confidential Information" means any technical, scientific or business
information provided by one Party to the other Party pursuant to this Agreement
or the July 8, 1998 Mutual Confidentiality Agreement between the Parties, in
connection with:

     (a)  this Agreement (including the negotiations and discussions leading
          up to the execution of this Agreement, and the specific terms of the
          Agreement),

     (b)  the AD7C(TM) Test and/or its efficacy, reagents, assays, operating
          procedures, test methods and technology,

     (c)  training with respect to the AD7C(TM) Test,

     (d)  Improvements in connection with the AD7C(TM) Test,

     (e)  compensation calculations and/or payments under this Agreement
          and/or any examination in connection therewith,

     (f)  Clinical Study Support information provided by Specialty to Nymox,

     (g)  marketing strategy, customer and contact lists, plans, or materials
          concerning the AD7C(TM) Test,

     (h)  applications or submissions to any regulatory authority or third
          party payer in connection with the AD7C(TM) Test, and/or

     (i)  arbitration proceedings pursuant to Paragraph 15.05.

"Confidential Information," other than the information described in
subparagraphs (a), (b) and (c) above, must either be disclosed in writing and
marked "Confidential" or, if orally or visually disclosed, must be confirmed in
writing as confidential within 30 days following the oral or visual disclosure.


                                       33


<PAGE>   4


"Contract Year" means a twelve-month period beginning on the first day of the
sixth month after the Launch of the AD7C(TM) Test by Specialty or an anniversary
of that date.

"Control" means the direct or indirect ownership of fifty (50%) or more of the
voting stock of the subject entity.

"Diagnostic Purposes" means the use or performance of the AD7C(TM) Test
primarily to aid the diagnosis of a patient by a physician and not for Clinical
Study Support.

"Effective Date" means the date of signature by the last Party to sign this
Agreement.

"Estimated Net Revenue" means, for a Clinical Study Support contract, which does
not stipulate a price per AD7C(TM) Test, the reasonable estimate made by
Specialty in good faith of the gross amount due to Specialty pursuant to that
contract for the performance of AD7C(TM) Tests, less any deductions for:

     (a)  any discounts, credits, allowances and/or refunds provided for in the
          contract;

     (b)  any established shipping, handling, or transportation charges to be
          paid to an independent third party by Specialty; and

     (c)  any sales taxes separately billed or accounted for.

If Specialty provides other services, assays or tests pursuant to a Clinical
Study Support contract, only that portion of the gross amount which represents
payment for AD7C(TM) Tests shall be considered Estimated Net Revenue.

"Estimated Number of Tests" means, for a Clinical Study Support contract, which
does not stipulate a price per AD7C(TM) Test, the reasonable estimate made by
Specialty in good faith of the number of AD7C(TM) Tests to be performed by
Specialty pursuant to that contract, less returns, re- dos or any "no
charge"tests.

"Improvement" means any advance, improvement or modification, whether or not
patentable, in the conduct of the AD7C(TM) Test, including, but not limited to
modifications of the method of conducting the AD7C(TM) Test or reagents used
therein.

"Know-How" means the information, knowledge and trade secrets relating to the
AD7C(TM) Test,  its reagents, assays, operating procedures, test methods and
technology.

"Launch" means the date of the first commercial performance of the AD7C(TM) Test
by Specialty for a third party.

"Minimum Test Volume" means 75% of the reasonable estimate made by Specialty in
good faith of the number of AD7C(TM) Tests it anticipates performing for
Diagnostic Purposes for a given Contract Year.

"Net Revenue" means the gross amount invoiced by Specialty in a given Billing
Month for the performance of AD7C(TM) Tests for Diagnostic Purposes, less:

                                       34
<PAGE>   5
     (a)  any usual discount, credit and/or refund;

     (b)  any trade and discount allowances or credits actually given;

     (c)  any bad debts;

     (d)  any amount excluded or disallowed by Medicare, Medicaid or a third
          party payer or insurance company;

     (e)  any established shipping, handling, or transportation charges paid to
          an independent third party by Specialty; and

     (f)  any sales taxes separately billed or accounted for.

If invoices include charges for assays, services or amounts which are not
AD7C(TM) Tests, only that portion of the invoiced amount which represents
AD7C(TM) Tests shall be considered Net Revenue.

"Number of Tests" means the number of AD7C(TM) Tests invoiced by Specialty in
each Billing Month, Billing Quarter or Contract Year, as appropriate, less
returns, re-dos or any "no charge" invoices.

"Nymox" means Nymox Corporation and its Affiliates.

"Party" means either Nymox or Specialty, or both, as will be apparent from the
context.

"Patents" means and collectively includes: (a) all of the United States and
patent applications listed in Exhibit A to this Agreement, together with any
reissues, extensions, continuations, divisions and continuations-in-part
thereof, and (b) any additional patents or patent applications which Nymox may
own or which Nymox may have or acquire the rights to license during the term of
this Agreement and which contain one or more claims which cover any aspect of
the AD7C(TM) Test.

"Specialty" means Specialty Laboratories, Inc. and its Affiliates.

"Trademarks" means the trademarks listed in Exhibit B.

ARTICLE 2.     PURPOSE OF AGREEMENT

The purpose of this agreement is to establish operations for the marketing and
conducting of the AD7C(TM) Test by Specialty in Specialty's reference
laboratories.

ARTICLE 3.     CONFIDENTIALITY

3.01      USE OF CONFIDENTIAL INFORMATION

Each Party will not use Confidential Information provided by the other Party for
any purpose other than the performance of this Agreement.

3.02      PROHIBITION ON THE DISCLOSURE OF CONFIDENTIAL INFORMATION TO THIRD
          PARTIES

                                       35
<PAGE>   6
Each Party will treat Confidential Information provided by the other Party with
the same degree of care as if it were its own confidential proprietary
information and will not disclose such Confidential Information to any third
party except as required by law, regulation, legal process or other governmental
authority or pursuant to this Agreement.

3.03      EXCEPTIONS

A.        Information Already Known or Independently Developed

Confidential Information shall not include information which:

     (a)  was known or used by the receiving Party, before disclosure, as
evidenced by its written or other tangible records made prior to the time of
receipt;

     (b)  has become known to the public other than through disclosure by the
receiving Party;

     (c)  a third Party having the right to disclose such information has
lawfully disclosed to the receiving Party; or

     (d)  the receiving Party developed independently of the Confidential
Information provided by the other Party as evidenced by the receiving Party's
written or other tangible records.

B.        Test Results

Specialty may disclose the results of the performance of an AD7C(TM) Test and
its interpretation to anyone authorized by law to receive such results.

C.        Consent to Disclose

A Party may disclose Confidential Information provided by the other Party with
the written consent of the disclosing Party.

D.        Requirements of Law

Nothing in this Agreement shall be deemed to prohibit the receiving Party from
disclosing any Confidential Information that is required by law, as determined
by the reasonable judgment of the receiving Party's attorney; provided, however,
that in the event of such legal requirement, prior to disclosing any
Confidential Information, the receiving Party shall notify the other Party of
the scope and source of such legal requirement and shall give the other Party
the opportunity to challenge the need to disclose and/or limit the scope of the
disclosed Confidential Information.

3.04      DURATION OF THE OBLIGATION TO MAINTAIN CONFIDENTIALITY

Each Party's obligations under this Article shall be in force during the term of
this Agreement and shall survive five (5) years after the termination or
expiration of this Agreement.

                                       36
<PAGE>   7


ARTICLE 4.  THE  LICENSE GRANT

4.01      SUBJECT MATTER OF THE LICENSE

Nymox hereby grants to Specialty a license to utilize all Nymox proprietary
technology, including its rights to the Patents and Know-How, necessary to
conduct the AD7C(TM) Test in a reference laboratory.

4.02      NATURE OF THE LICENSE GRANTED

A.        AD7C(TM) Test

Specialty's license to market and perform the AD7C(TM) Test shall include the
following:

     (a)  Specialty's license is semi-exclusive for conducting the AD7C(TM) Test
          for Diagnostic Purposes.  Nymox retains the right to conduct the
          AD7C(TM) Test for Diagnostic Purposes and the right to market, license
          and sell kits to third parties for conducting the AD7C(TM) Test for
          Diagnostic Purposes and to license its AD7C(TM) Test Patents, Know-How
          and technology to third parties in order to develop a kit for
          conducting the AD7C(TM) Test.

     (b)  Specialty's license is exclusive for conducting the AD7C(TM) Test for
          Clinical Study Support.  Notwithstanding the foregoing, Nymox retains
          the right to conduct the AD7C(TM) Test in connection with Nymox's
          research and development activities, including Nymox's own clinical
          trials and third party clinical trials evaluating Nymox's therapeutics
          for Alzheimer's disease, and in connection with the clinical trials of
          a strategic partner of Nymox.  (It is understood for the purposes of
          this Paragraph that any agreement establishing such a strategic
          relationship shall include other substantive activities (e.g. equity
          investment, R&D funding etc.) beyond assay services for the clinical
          trials.) Nymox shall inform Specialty of the name of any such
          strategic partner in a timely manner and the number of strategic
          partners shall not exceed three. However, Nymox shall not have the
          right to market or sell any kits for conducting the AD7C(TM) Test in
          connection with any clinical trials or to grant licenses for that
          purpose.

     Specialty shall have the right to conduct the AD7C(TM) Test on all specimen
     types, including but not limited to, cerebrospinal fluid (CSF), urine and
     blood.

B.        Trademarks

Specialty's license includes the right to use the Nymox Trademarks, "AD7C(TM)"
and "Nymox," in connection with the promotion, education, marketing and
performance of the AD7C(TM) Test, subject to Nymox's right to approve marketing
materials as set out below in Article 7.


                                       37
<PAGE>   8


4.03      TERRITORY

Specialty's license to conduct the AD7C(TM) Test and to use the Nymox and AD7C
Trademarks is for the United States and its territories and possessions.

4.04      TERM

The initial term of the license is for twenty-four (24) months from the date of
Launch by Specialty of the AD7C(TM) Test.  The parties anticipate that Specialty
will launch the AD7C(TM) Test within two months of the Effective Date.  The
Agreement shall automatically renew for two (2) additional one (1) year terms,
unless terminated earlier pursuant to Article 9.

4.05      NON-TRANSFERABLE; NO SUBLICENSING

Specialty's license is not transferable or assignable and Specialty is not
entitled to sublicense or to use this license as collateral or security in any
lending, financing or other agreement.  Nymox shall not transfer or assign this
Agreement, or any Nymox obligations under this Agreement, to any third party.

4.06      LAUNCH REQUIREMENTS

In order to enable Specialty to achieve timely Launch, Nymox must fulfill its
obligations under Paragraphs 11.02 (1), (2) and (3)  within ten (10) days of the
Effective Date of this Agreement.

ARTICLE 5.               COMPENSATION TO NYMOX

5.01      COMPENSATION FOR TESTS CONDUCTED FOR DIAGNOSTIC PURPOSES

For AD7C(TM) Tests conducted by Specialty for Diagnostic Purposes, the
compensation owed to Nymox by Specialty for each Billing Month will be
calculated as follows:

     (1)  Where the Average Price for the AD7C(TM) Tests conducted for
          Diagnostic Purposes for a Billing Month is more than $200:

          Compensation = ($82 + 60% x (Average Price -$200)) x Number of Tests.

     (2)  Where the Average Price for the AD7C(TM) Tests conducted for
          Diagnostic Purposes for that Billing Month is $200 or less:

          Compensation = $82 x  Number of Tests.

                                       38
<PAGE>   9


5.02      COMPENSATION FOR TEST CONDUCTED FOR CLINICAL TRIALS

For AD7C(TM) Tests conducted by Specialty for Clinical Study Support, the
compensation owed to Nymox by Specialty will be calculated and reported
separately for each Clinical Support Study contract, on a quarterly basis.  For
each Clinical Study Support contract executed by Specialty, the compensation to
Nymox will be calculated for each Billing Quarter as follows:

     (1)  Where the Average Price for the AD7C(TM) Tests conducted under that
          contract is more than $200:

          Compensation = ($51.25 + 25% x (Average Price - $200)) x number of
          tests actually conducted during that Billing Quarter

     (2)  Where the Average Price for the AD7C(TM) Test conducted under that
          contract is $200 or less:

          Compensation = $51.25 x number of tests actually conducted during that
          Billing Quarter.

5.03      INTRODUCTION OF A KIT

If Nymox or a Nymox licensee introduces a kit for sale or license to third
parties for conducting the AD7C(TM) Test for Diagnostic Purposes, Nymox and
Specialty agree to renegotiate the compensation package in keeping with the
spirit of this Agreement in order to enable Specialty to market and conduct the
AD7C(TM) Test on a competitive basis with Nymox and third parties offering such
kits.

5.04      PAYMENT OF COMPENSATION

Compensation payments will be made quarterly and will be due and payable within
30 days of the closing of each calendar quarter.

Each compensation payment shall be accompanied by an itemized statement
detailing how the compensation was calculated.

For AD7C(TM) Tests conducted for Diagnostic Purposes, the itemized statement for
each compensation payment shall include for each Billing Month in that payment
period: 

     (a)  the Net Revenue, specifying the gross amount invoiced for the
          performance of the AD7C(TM) Test by Specialty and the amount of each
          deduction; 

     (b)  the Number of Tests; and 

     (c)  the Average Price.

For each Clinical Study Support contract, the itemized statement for each
Billing Quarter shall include, as applicable, : 

     (a)  the Estimated Net Revenue, including the gross amount estimated to be
          invoiced for the performance of the AD7C(TM) Test by Specialty and the
          estimated amount of each deduction;

                                       39
<PAGE>   10


     (b)  the Estimated Number of Tests;

     (c)  the Average Price; and

     (d)  the number of tests actually conducted during the Billing Quarter.

5.05      RIGHT TO EXAMINE RECORDS

During the term of this Agreement and for one year after its termination or
expiration, Nymox shall have the right to retain an independent certified public
accounting firm, to which Specialty has no reasonable objection, to examine the
relevant books and records of Specialty to verify the calculation and payment of
compensation owed to Nymox under this Agreement. Specialty may require the
accounting firm to sign a confidential disclosure agreement before the
examination is conducted. The accounting firm will only report the results of
its examination with respect to the accuracy of the calculation, payment and
reporting to Nymox (specifying any inaccuracies found) and shall not disclose to
Nymox any other information it obtained. Only one such examination may be
conducted a year and any examination shall be conducted during reasonable
business hours. Specialty agrees to cooperate with the examination and to
provide any financial, business or laboratory records requested by the
accounting firm or used by Specialty in calculating the compensation. The
accounting firm shall give reasonable notice of an examination date sufficient
to allow Specialty to organize its records. Nymox shall bear the costs of any
such examination unless the examination results in an adjustment in its favor,
which adjustment is at least the greater of $50,000 or more or 5% of the total
compensation paid by Specialty for the payment period under examination, in
which case Specialty will bear the cost of the examination.

Nymox and Specialty agree to be bound by the results of any such examination and
to pay to the other Party any sums found owing within 30 days of the examination
report.

ARTICLE 6.  REIMBURSEMENT AND PRICE

6.01      PRICE

The Parties anticipate that Specialty will initially invoice the performance of
the AD7C(TM) Test at the current market price of $400 per test, but recognize
that Specialty may change the invoice price in the future because of cost
factors, reimbursement patterns or other market considerations.

6.02      CLINICAL STUDY SUPPORT

For AD7C(TM) Tests to be conducted by Specialty for Clinical Study Support,
Specialty may negotiate contracts and set prices, for example, based on volume
commitments.

Both parties agree to review clinical studies on a case by case basis.

Nymox has the right to review any proposed clinical study before Specialty
enters into a Clinical 

                                       40
<PAGE>   11
Study Support contract with respect to such study and the right to approve the
parties conducting them, such approval not to be unreasonably withheld. For any
proposed Clinical Study Support contract, Specialty shall disclose to Nymox the
names of the party(ies) who will be conducting the study and the nature of the
study. Nymox shall notify Specialty within 10 days of receiving the relevant
information from Specialty whether Nymox objects. Nymox must demonstrate a
reasonable basis for any objection to the party(ies) conducting the study.

Specialty agrees to make it a term of any Clinical Study Support contract that
the other party agree that any AD7C(TM) Tests performed pursuant to that
contract be only for the purposes of Clinical Study Support.

6.03      REIMBURSEMENT

The Parties agree to use reasonable efforts to share all information concerning
reimbursement for the AD7C(TM) Test and to cooperate fully with each other about
obtaining reimbursement for the AD7C(TM) Test from physicians, hospitals,
patients and third party payers.

ARTICLE 7. MARKETING

7.01      SHARING MARKETING EXPENSES

Nymox shall share all direct marketing and promotional costs incurred by
Specialty on the following basis:

     (a)  50%/50% for the direct marketing and promotional costs for the conduct
          of the AD7C(TM) Test for Diagnostic Purposes, provided that Specialty
          be reimbursed a minimum of $10,000 per year for such activities, with
          amounts above that being subject to Nymox's approval at its sole
          discretion.

     (b)  0%(Nymox)/100%(Specialty) for the direct marketing and promotional
          costs for the conduct of the AD7C(TM) Test for Clinical Study Support
          purposes during any period when Specialty's license for Clinical Study
          Support is exclusive; and

     (c)  50%/50% for the direct marketing and promotional costs for the
          conducting of the AD7C(TM) Test for Clinical Study Support during any
          period when Specialty's license for Clinical Study Support purposes is
          nonexclusive, provided that Specialty be reimbursed a minimum of
          $10,000 per year for such activities, with amounts above that being
          subject to Nymox's approval at its sole discretion.

7.02      APPROVAL OF MARKETING STRATEGY

Nymox has the right to review and approve Specialty's marketing materials and
literature and marketing strategy which approval shall be given within 10 days
of receiving all the relevant information from Specialty; any such approval
shall not be unreasonably withheld.

                                       41


<PAGE>   12
7.03      SPECIALTY TRADEMARKS

Nothing herein shall restrict the right of Specialty to use its own trademarks
and logos on any and all marketing materials, literature, invoices, reports and
the like in connection with its license under this Agreement.

ARTICLE 8. PERFORMANCE TARGETS/CONVERSION TO NONEXCLUSIVE 
           LICENSE

8.01      SPECIALTY EFFORTS

Specialty shall use commercially reasonable efforts to market and conduct the
AD7C(TM) Test.

8.02      TEST VOLUME ESTIMATE

Before the start of each Contract Year, Specialty shall make a reasonable
estimate in good faith of the number of AD7C(TM) Tests it anticipates performing
for Diagnostic Purposes and for Clinical Study Support purposes for a given
Contract Year and give Nymox written notice of such estimate at least 30 days
before the start of that Contract Year. 

8.03      COMPENSATION FOR FAILURE TO MEET MINIMUM TEST

If Specialty's actual Number of Tests in a Contract Year do not meet the Minimum
Test Volume for that Contract Year, Specialty shall have the right to maintain
its semi-exclusive license rights for the following Contract Year by paying
Nymox its lost compensation caused by the deficiency. The lost compensation
would be calculated as follows:

     (1)  Determine the shortfall in the number of tests:

          Annual Shortfall = Minimum Test Volume - Number of Tests in the
          Contract Year

     (2)  Convert to monthly shortfall:

          Monthly Shortfall in Number of Tests = Annual Shortfall/12.

     (3)  For each Billing Month in the Contract Year, use the Monthly Shortfall
          in Number of Tests as the "Number of Tests" in the appropriate
          Paragraph 5.01 formula in order to calculate the lost compensation for
          that Billing Month.

     (4)  Total the calculated lost compensation revenues for the Billing Months
          of the Contract Year to arrive at the lost compensation.



                                       42
<PAGE>   13
The lost compensation would be due and payable within 30 days of the calendar
quarter immediately following the end of the Contract Year in order for
Specialty to maintain its semi-exclusive license for Diagnostic Purposes. If
Specialty's failure to meet the Minimum Test Volume is due to Nymox's failure to
fulfil its obligations under Paragraph 11.04, or Nymox's failure or refusal to
approve Specialty's marketing materials or strategy under Paragraph 7.02, then
Paragraph 8.03 shall not apply.

8.04      FAILURE TO PAY COMPENSATION

If Specialty fails to pay the lost compensation due pursuant to Paragraph 8.03,
then Nymox has the option of either converting to nonexclusive Specialty's
license for conducting the AD7C(TM) Test for Diagnostic Purposes or terminating
that portion of the Agreement. Nymox shall give Specialty 90 days written notice
of its intent to exercise either option. Notwithstanding the foregoing, if
Specialty's failure to meet the Minimum Test Volume is due to Nymox's failure to
fulfil its obligations under Paragraph 11.04 or Nymox's failure or refusal to
approve Specialty's marketing materials or strategy under Paragraph 7.02, then
Paragraph 8.04 shall not apply.

8.05      CONVERSION TO NONEXCLUSIVE LICENSE

If Nymox exercises its option under Paragraph 8.04 to convert Specialty's
license to nonexclusive and then licenses one or more third parties to conduct
the AD7C(TM) Test, the compensation to Nymox from Specialty would be the lesser
of:

     (a)  the compensation which would have been due under this Agreement had
          the license remained semi-exclusive; or

     (b)  the compensation as calculated under any applicable portions(s) of the
          third party license.

ARTICLE 9. TERMINATION

9.01      TERMINATION FOR MATERIAL BREACH

Either Party has the right to terminate the Agreement for material breach by the
other Party upon thirty (30) days written notice specifying the breach. The
other Party has thirty (30) days from the receipt of the notice to cure the
breach, failing which the Agreement shall immediately terminate upon the sending
of a second notice of termination to the other Party. A material breach includes
(but is not limited to) a failure or refusal to pay compensation which is
actually due and owing pursuant to Paragraphs 5.04 and 5.05. 

9.02      TERMINATION FOR FAILURE TO LAUNCH TEST

Subject to Nymox having fulfilled its obligations under Paragraph 4.06, if
Specialty does not launch the AD7C(TM) Test within two months following the
Effective Date, Nymox can give Specialty 60 days notice of its intent to
terminate this Agreement. If during that 60 day period, Specialty launches the
AD7C(TM) Test, the Agreement shall not be terminated for this reason.


                                       43


<PAGE>   14


9.03      TERMINATION FOR FAILURE TO PAY LOST COMPENSATION REVENUE

If Specialty fails to pay Nymox lost compensation due pursuant to Paragraph 8.03
and Nymox gives Specialty notice of its intent to terminate the Diagnostic
Purpose portion of Agreement pursuant to Paragraph 8.04, Nymox may so terminate
if Specialty has not paid the lost compensation within the 90 day notice period.
If during that 90 day period, Specialty pays the lost compensation, all license
rights under this Agreement shall continue in full force and effect.

9.04      TERMINATION ON BANKRUPTCY 

A.        Nymox may elect to terminate this Agreement upon Specialty becoming
          bankrupt, making an assignment in bankruptcy or an assignment for the
          benefit of its creditors, coming under receivership, whether as a
          result of court order, the provisions of a contract or agreement or
          government action or otherwise being unable to meet its financial
          obligations as they become due.

B.        In the event of Nymox becoming bankrupt, entering into bankruptcy
          proceedings (voluntary or otherwise) or coming under receivership,
          Specialty may elect to retain its license rights under this Agreement
          if the trustee, receiver or other entity so authorized by a federal
          bankruptcy court, seeks to reject Specialty's license.  Upon such
          election, the rights and remedies of the Parties shall continue to be
          governed by the terms of this Agreement.

9.05      TERMINATION FOR FORCE MAJEURE

Should force majeure as described in Paragraph 15.01 make substantial
performance of this Agreement impossible for more than one hundred and eighty
(180) then the Party not affected by the force majeure may give a thirty (30)
day notice of termination of this Agreement pursuant to Paragraph 15.01 and if
the Party affected is unable to restore substantial performance of this
Agreement in that thirty (30) day notice period, the Agreement shall be
terminated.

9.06      TERMINATION FOR COMPETITOR ACQUIRING CONTROL

If a Competitor acquires control of Specialty during the term of this Agreement,
Nymox may terminate this Agreement on three (3) months written notice to
Specialty.

9.07      EFFECT OF TERMINATION OR EXPIRATION

Upon the termination or expiration of this Agreement, Specialty shall:

     (a)  return to Nymox any unused reagents, antibodies, proteins, specimens,
          protocols, promotional material and other property provided by Nymox
          for the conducting of the AD7C(TM) Test, provided that copies or
          samples may be retained by Specialty for record purposes;



                                       44
<PAGE>   15


     (b)  cease receiving specimens which are provided to Specialty solely for
          conducting the AD7C(TM) Test and cease conducting the AD7C(TM) Test
          with the exception of conducting AD7C(TM) Tests on specimens that
          Specialty had already received prior to the termination or expiration
          of this Agreement; 

     (c)  cease using the "AD7C(TM)" and "Nymox" trademarks and marketing the
          AD7CT(TM) Test. 

It shall not be considered "use" or "marketing" to continue use of the
Trademarks in Specialty's then-current catalog or previously printed marketing
materials which include assays or services other than the AD7C(TM) Test,
provided that Specialty shall remove the Trademarks from all catalogs and
marketing materials at the next scheduled revision.

The termination or expiration of this Agreement shall not affect any rights or
obligations which may have accrued to either Party prior to the termination or
expiration date, including the obligation for compensation as outlined in
Article 5.

Upon the termination or expiration of this Agreement, all rights that Nymox
licensed to Specialty under this Agreement revert to Nymox in their entirety,
subject only to Specialty's retained rights pursuant to Paragraph 10.01 which
shall remain in effect following termination or expiration.  It is understood
that this paragraph applies only to the termination of the Agreement in its
entirety, and not to termination of the Diagnostic Purposes portion of the
Agreement pursuant to Paragraph 9.03.  

ARTICLE 10.  IMPROVEMENTS

10.01     SPECIALTY'S IMPROVEMENTS

If Specialty makes any Improvements during the term of this Agreement, it shall
disclose such Improvements to Nymox in a timely manner, and such Specialty
Improvements shall become the property of Nymox.  Specialty shall thereafter
have the right to use such Specialty Improvements according to the terms of
Specialty's license under this Agreement, without payment of any additional
compensation for the use of any such Specialty Improvement(s).  Specialty shall
execute any documents necessary for Nymox to secure its property interests in
the Specialty Improvements.

In addition, Specialty shall retain an irrevocable, fully-paid, royalty-free,
nonexclusive worldwide license to practice the Specialty Improvements in all
areas and applications outside the subject matter of this license during the
term of this Agreement and following its termination or expiration, to the
fullest extent permitted by applicable law

Nothing in this Agreement shall be construed as granting to Specialty any
express or implied license or right under any of the Patents after the
expiration or termination of this Agreement.

10.02     NYMOX IMPROVEMENTS

                                       45
<PAGE>   16
If Nymox makes any Improvements during the term of this Agreement, it shall
promptly disclose such Improvements to Specialty, and Specialty shall thereafter
have the right to use such Nymox Improvements according to the terms of its
license under this Agreement.

ARTICLE 11.  RESPONSIBILITIES OF THE PARTIES

11.01     SPECIALTY'S RESPONSIBILITIES

Specialty's responsibilities under this Agreement include:

     (1)  at its expense, specimen collection and shipping, specimen storage,
          reporting of results, billings and collections and any other
          additional related tasks that the Parties may agree upon;

     (2)  at its expense, performance of the AD7C(TM) Test, including the
          provision of the necessary personnel, supplies (other than the Nymox
          reagents and materials referred to in Paragraph 11.02(3)) and
          equipment;

     (3)  at its expense, inclusion of the AD7C(TM) Test in Specialty's
          directory of services;

     (4)  at its share of the expenses as set out in Article 7, marketing and
          promotional activities for the AD7C(TM) Test; and

     (5)  at its expense, the wages and benefits of Specialty personnel during
          their training by Nymox in connection with performance of the AD7C(TM)
          Test.

11.02     NYMOX'S RESPONSIBILITIES

Nymox's responsibilities under this Agreement include:

     (1)  at its expense, provision of AD7C(TM) Test protocols, sufficient
          clinical specimens for assay validation, quality control procedures
          and technology transfer as may be required for Specialty to perform
          the AD7C(TM) Test to Nymox's specifications and to obtain AD7C(TM)
          Test results consistent with those obtained by Nymox personnel
          experienced in conducting the AD7C(TM) Test;

     (2)  at its expense, training of such Specialty personnel as may be
          required for Specialty to perform the AD7C(TM) Test to specifications;

     (3)  at its expense, supply of the Nymox proprietary and non-proprietary
          materials and reagents needed for Specialty to perform the AD7C(TM)
          Test as further specified in Paragraph 11.04;

     (4)  at its expense, provision of technical support, including
          interpretation support, technical service support, and confirmation
          testing to be conducted by Nymox at the request of Specialty;

                                       46
<PAGE>   17


     (5)  at its share of the expenses as set out in Article 7, assisting the
          marketing and promotional activities for the AD7C(TM) Test carried out
          by Specialty, including assisting with the preparation of Specialty
          promotional materials for the AD7C(TM) Test, as requested by
          Specialty, and approving all Specialty promotional materials for the
          AD7C(TM) Test, such approval not to be unreasonably withheld pursuant
          to Paragraph 7.02; and

     (6)  at its expense, sole responsibility for payment of any license fees,
          royalties or other compensation which may be owed to a third party to
          secure the right to market and perform the AD7C(TM) Test.

11.03     SHARED TRAVEL AND ACCOMMODATION EXPENSES

Specialty and Nymox agree to share any travel and accommodation expenses 50%/50%
incurred prior to the Effective Date as a result of either Party's personnel
having to travel to the other Party's facilities for training, technology
transfer, quality control or other reason relating to the performance of the
AD7C(TM) Test to specifications.  Any future such travel expenses shall be
shared 50%/50% only if mutually agreed upon in advance.

11.04     SUPPLY OBLIGATIONS

Nymox shall supply to Specialty all materials and reagents necessary for the
conduct of the AD7C(TM) Test as the conduct of the test is specified by Nymox.
All such materials and reagents shall meet all specifications and quality
requirements then in effect for Nymox's own conduct of the AD7C(TM) Test and,
Nymox shall provide Specialty with its data and specifications concerning the
stability and shelf life of  the materials and reagents, including any changes
or new information, on an ongoing basis.

During the period prior to the start of the Contract Year, Nymox shall supply
materials and reagents to Specialty every two (2) months, in an amount
sufficient to conduct at least 500 AD7C(TM) Tests. Such materials and reagents
shall have a shelf life of no less than two (2) months.

During each Contract Year, Nymox shall supply materials and reagents to
Specialty on a quarterly basis, in amounts sufficient for Specialty to conduct
one-fourth (1/4) of the test volume estimates in Paragraph  8.02.  Such
materials and reagents shall have a shelf life of no less than three months.

In the event Specialty needs additional quantities of materials and reagents,
Specialty shall notify Nymox in writing of its additional needs, and Nymox shall
use reasonable efforts to supply the materials and reagents in a timely manner.

11.05     LIMITATIONS ON LIABILITY




                                       47
<PAGE>   18
In no event shall either Party be liable to the other in contract, tort, product
liability or otherwise for special, indirect, incidental, consequential or
punitive damages.

Each Party is responsible for:

     (1)  the safety of its own employees and agents while engaged in work at
          its own facility pursuant to this Agreement, and

     (2)  any liability for damages or personal injuries, including death,
          resulting from work conducted by that Party's own employees and agents
          pursuant to this Agreement, without any warranty, liability or
          indemnification on the part of the other Party unless such damages or
          personal injuries are due to the negligence or wilful misconduct of
          such other Party or employees or agents of such other Party.

11.06     INFRINGEMENT

A.        Notice of Suspected Patent Infringement

Specialty shall promptly inform Nymox in writing of any suspected infringement
of the Patents by a third party and Nymox shall make reasonable efforts with the
cooperation of Specialty to ascertain in a timely manner whether the third party
is infringing or has infringed the Patents. Nymox shall communicate in writing
the results of its investigation into the suspected infringement to Specialty.

B.        Purported Patent Infringement

If the result of Nymox's investigation is that Nymox believes an infringement
has occurred, is occurring or on reasonable ground is believed likely to occur,
Nymox will have six months either to halt such infringement (including by
licensing such third party if Specialty's license has been converted to
nonexclusive pursuant to Paragraph 8.04 or by written agreement by such third
party to cease any infringement) or to initiate litigation against the
infringing third party (including authorizing Specialty, with Specialty's
consent, to initiate such litigation). Specialty agrees that it will, at
Nymox's request and expense, furnish reasonable cooperation and assistance.

C.        Nymox's Failure or Refusal to Take Action Within Six Months

Nymox may initiate infringement litigation with respect to Patent(s) owned by
Nymox relating to the AD7C(TM) Test, in the sole discretion of Nymox. In the
event that Nymox, for any reason, does not halt the infringement or initiate
litigation within the six months as set out in Paragraph 11.06(B), Specialty's
compensation obligations shall be reduced by one-half until the infringement is
discontinued and Specialty may elect, in its discretion, to bring an action in
its own name, or, if required by law to bring such action in the name of the
holder of the patent, in the name of Nymox. If Specialty elects to bring an
action against an alleged infringer under this paragraph, Nymox will cooperate
with Specialty in the litigation and Specialty shall bear the cost and expenses
incurred in 

                                       48
<PAGE>   19
relation to the litigation subject to Specialty's right to withhold and be
forgiven compensation payments which otherwise would be payable to Nymox, not to
exceed Specialty's out-of-pocket expenses for bringing and maintaining such
action.  From such time as the infringement ceases (whether voluntarily or by
court order), Specialty's full compensation obligations to Nymox would resume.

D.        Infringement Proceedings

No settlement, consent judgement, or other voluntary disposition of the
litigation which may have an adverse effect on the rights of one party may be
entered into without the consent of that Party.

The Party initiating any infringement litigation, whether with or without the
consent of the other Party, shall bear the costs of litigation against
infringers (subject to Specialty's rights to withhold compensation under
Paragraph 11.06(C)) and shall receive all damages and recoveries awarded in such
instance; provided, however, that in the event of such an award to Specialty,
Nymox shall first be paid the amount of the withheld compensation (if any).

ARTICLE 12.  QUALITY CONTROL

12.01     STANDARD OF QUALITY

Specialty shall conduct the AD7C(TM) Tests in compliance with Nymox's written
specifications and standard operating procedures (provided that such have been
conveyed to Specialty in writing) and to the standards of a fully-certified
reference laboratory.

12.02     QUALITY CONTROL Specialty acknowledges that Nymox has the right to
ensure that Specialty performs the AD7C(TM) Test to the standard of quality set
out in Paragraph 12.01 and agrees to cooperate fully with Nymox's exercise of
that right.  Without limiting this general right, Nymox has the specific rights
to:

     (1)  have Specialty furnish Nymox with any pertinent information about its
          procedures, records, notes and results for the AD7C(TM) Test,
          including such information about specific test results (subject to any
          legal requirements to maintain patient confidentiality) to enable
          Nymox to verify Specialty's compliance with Paragraph 12.01 in the
          event of any apparent discrepancies or, in the absence of
          discrepancies, not more than once per Contract Year;

     (2)  have Specialty supply Nymox with samples of specimens, reagents or
          other material or supplies for Nymox's own testing for the
          verification of Paragraph 12.02(1), to the extent reasonably available
          and not needed for other Specialty testing; and

                                       49
<PAGE>   20


     (3)  upon ten (10) days written notice and at a mutually agreeable time,
          not more than once per Contract Year, to inspect any facility
          conducting or assisting in the conducting of AD7C(TM) Tests and any
          laboratory records, documents, reports or other information relating
          to the conducting of AD7C(TM) Tests, test any reagents, equipment or
          other supplies and material used in the conducting of AD7C(TM) Tests
          (to the extent reasonably available and not required for other
          Specialty testing, and provided that Specialty approve the competence
          and qualification of any person prior to allowing tests of Specialty
          equipment) and interview any laboratory personnel directly involved in
          the conducting of AD7C(TM) Tests.

ARTICLE 13.  EFFECT OF LICENSING AGREEMENT

13.01     NO AGENCY RELATIONSHIP ESTABLISHED

Neither Party would be an agent, representative, contractor nor employee of the
other.

13.02     NO TRANSFER OF INTELLECTUAL PROPERTY RIGHTS

Nymox retains all of its patent rights, trademarks, copyrights, trade secrets
and other proprietary rights covering or relating to the AD7C(TM) Test and
nothing in this Agreement shall be construed as assigning, alienating or
transferring any of these rights to Specialty, except as specifically provided
in the license grants of this Agreement.

13.03  NO SALE OF PROPRIETARY REAGENTS

Nymox retains ownership to any proprietary reagents it supplies to Specialty
under the terms of this Agreement.  Specialty agrees to use any reagents
supplied by Nymox for the conducting of the AD7C(TM) Test pursuant to this
Agreement and not to give, transfer or sell any of these reagents to any third
party without the written consent of Nymox.

ARTICLE 14.  REPRESENTATIONS AND WARRANTIES

14.01     WARRANTY OF RIGHTS IN THE SUBJECT MATTER OF LICENSE

Nymox warrants that it owns the rights to the Patents listed in Exhibit A and
the Trademarks listed in Exhibit B to this Agreement and that it has the
authority to grant licenses to use these Patents and Trademarks and its Know-How
concerning the AD7C(TM) Test and its performance as provided herein.

14.02     WARRANTY OF SUPPLIES

Nymox warrants that the AD7C(TM) Test materials and reagents it supplies to
Specialty will meet the internal specifications and quality requirements used by
Nymox for those materials and reagents at the time they are shipped.



                                       50
<PAGE>   21
14.03     DISCLAIMER OF WARRANTY

Other than the warranties set out in Paragraph 14.01 and 14.02, Nymox makes no
express or implied warranties about the AD7C(TM) Test materials supplied by
Nymox and used by Specialty pursuant to this Agreement or about the AD7C(TM)
Test, including but not limited to the implied warranties of merchantability and
fitness for a particular purpose.

14.04     REPRESENTATIONS

A.        Nymox represents to Specialty that, to the best knowledge of Nymox, as
          of the Effective Date:

     (1)  There are no claims, actions, suits or proceedings, pending or
          threatened, which relate in any way to the marketing or performance of
          the AD7C(TM) Test;

     (2)  There are no claims, actions, suits or proceedings, pending or
          threatened, which allege that marketing or performance of the AD7C(TM)
          Test infringes the patent, trademark or other rights of a third party;
          and

     (3)  Nymox is not aware of any third party patent(s) which would be
          infringed by Specialty's marketing an/or performance of the AD7C(TM)
          Test.

B.        Specialty represents to Nymox that:

     (1)  Prior to Launch, Specialty will have clinically validated the AD7C(TM)
          Test; and

     (2)  Specialty shall treat the AD7C(TM) Test in the same manner as other
          tests included in Specialty's directory of services and agrees to
          comply with applicable regulatory requirements.

ARTICLE 15. MISCELLANEOUS PROVISIONS

15.0      FORCE MAJEURE

The performance by either Party of any covenants or obligations to be performed
under this Agreement shall be excused by reason of strikes or other labor
disturbances, riots, fires, floods, earthquakes, accidents, wars, embargoes,
delays of carriers, inability to obtain materials from sources of supply, or
acts, injunctions or restraints of governments or any cause beyond the control
of the Parties preventing such performance whether similar or dissimilar to the
foregoing, provided, however, that:

     (1)  the Party affected shall inform the other of the occurrence of the
          force majeure condition as soon as practicable;

     (2)  the Party affected shall exert its reasonable diligent efforts to
          eliminate or cure or overcome any such causes and to resume
          performance of its covenants and obligations as soon as practicable;
          and 


                                       51



<PAGE>   22
     (3)  should the force majeure condition make substantial performance of
          this Agreement impossible for more than one hundred eighty (180) days
          then the Party not affected may give a thirty (30) day notice of
          termination of this Agreement and if the Party affected is unable to
          restore substantial performance of this Agreement in that thirty (30)
          day notice period, the Agreement shall be terminated.

15.0      PUBLIC STATEMENTS

Nymox and Specialty shall mutually develop and approve in writing any press
releases or announcements about this Agreement or about any activities by either
Party relating to this Agreement. Neither Party shall publicly disclose the
specific terms of this Agreement except as required by law or regulation or with
the consent of the other Party or unless there has been a prior public
disclosure of the information by the other Party.

15.03     NOTICES

Any notice or other communication required by this Agreement shall be in writing
and shall be effective if hand delivered or if sent by certified or registered
mail or by facsimile transmission to the following locations until notified
otherwise in writing.

Nymox Pharmaceutical Corporation

     Attention: President
     Nymox Pharmaceutical Corporation
     9900 Boul. Cavendish, Suite 306
     Saint Laurent Quebec
     Canada  H4M 2V2
     FAX: (514) 332-2227

Specialty Laboratories, Inc.

     Attention: President
     Specialty Laboratories, Inc.
     2211 Michigan Avenue
     Santa Monica, CA  90409-3900
     FAX: (310) 828-9413

A notice is effective on the date of delivery to the Party. Delivery is deemed
to have occurred on the day of delivery by courier, or upon facsimile
transmission with confirmation, or on the fifth day after the date of sending
the notice by registered mail.

15.04     GOVERNING LAW


                                       52

<PAGE>   23
This Agreement shall be governed by, construed and enforced in accordance with
the laws of the State of California.

15.05     DISPUTE RESOLUTION

In the event of any controversy or claim arising out of or relating to any
provisions of this Agreement or the breach thereof, the Parties shall try to
settle those conflicts amicably between themselves.  Should they fail to agree,
the matter in dispute shall be settled through arbitration conducted by and in
accordance with the rules of the American Arbitration Association ("A.A.A.").

Either Party may furnish the other party with a dated, written notice (the
"Arbitration Notice") indicating (I) intent to commence arbitration proceedings,
(ii) the nature, with reasonable detail, of the dispute, (iii) the amount
involved, if any, and (iv) the remedy sought.  The arbitration shall be held at
a neutral place mutually agreeable to the parties.  Within thirty (30) days of
the date of the Arbitration Notice, each party shall select one (1) Arbitrator,
who shall not be a current or former employee, agent, consultant or other
representative of either party; the two selected Arbitrators shall appoint a
third, neutral, Arbitrator.

The arbitration award shall be final and binding.  Either party may enter any
such award in a court having jurisdiction or may make application to such court
for judicial acceptance of the award and an order of enforcement, as the case
may be.

15.06     CURRENCY

All references to money in the Agreement refer to U.S. dollars and all payments
made under this Agreement shall be in that currency.

15.07     PARTIAL INVALIDITY

If any provision of this Agreement be held invalid, illegal or unenforceable,
such invalidity, illegality or unenforceability shall not affect any other
provision of this Agreement and the Parties shall use reasonable efforts to
substitute a valid, legal and enforceable provision which, as far as
practicable, implements the purposes and intent of the provision held invalid,
illegal or unenforceable.  If the Parties are unable to arrive at such a
substitute, this Agreement shall be construed as if such invalid, illegal or
unenforceable provision had never been contained in it, provided that the
performance required under this Agreement with such a provision deleted remains
substantially consistent with the intent of the Parties.

15.08     WAIVER

Failure to require performance of any provision of this Agreement does not waive
a Party's right to demand compliance with that provision at a later time.
Waiver of any default shall not waive any other default.

                                       53
<PAGE>   24


15.08     ENTIRE AGREEMENT

This Agreement contains the entire agreement between the Parties with respect to
the subject matter covered by this Agreement.  No representations, whether oral
or written, made before this Agreement is executed shall amend this Agreement.
Any modification or amendment to this Agreement shall be in writing and signed
by an authorized officer of each Party.

IN WITNESS THEREOF, the undersigned have executed this Agreement as of the dates
set forth below:

ACCEPTED AND AGREED TO:

     Nymox Corporation                              Specialty Laboratories, Inc.



--------------------------------------------------------------------------------
     Paul Averback                                  Paul Beyer
     President                                      President


EXHIBIT A:  PATENTS LICENSED TO SPECIALTY

U.S Patent Number                       Title
-----------------                       -----
5,830,670                               Neural Thread Protein Gene Expression 
                                        and Detection of Alzheimer's Disease

U.S. Patent Application Number          Title
------------------------------          -----
08/450,673                              Neural Thread Protein Gene Expression 
                                        and Detection of Alzheimer's Disease

08/469,629                              Neural Thread Protein Gene Expression 
                                        and Detection of Alzheimer's Disease

08/340,426                              Method of Detecting Neurological Disease
                                        or Dysfunction

                                       54
<PAGE>   25



EXHIBIT B:  TRADEMARKS LICENSED TO SPECIALTY
The Trademark             AD7C(TM)

The trademarks on this page are reasonable facsimiles of the actual Trademarks.

Nymox will furnish Specialty with materials necessary for reproduction of the
actual Trademarks on Specialty promotional materials.


                                       55